ISRCTN35472475 https://doi.org/10.1186/ISRCTN35472475

Markers of endothelial activation and damage in haematological patients in relation to efficacy of transfusion support: a pilot study

Submission date 07/03/2007	**Recruitment status** No longer recruiting	[X] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [_] Record updated in last year
Registration date 07/03/2007	**Overall study status** Completed	
Last Edited 02/09/2008	**Condition category** Haematological Disorders	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr J L H Kerkhoffs

Contact details
Haga Hospital
Leyweg 275
Den Haag
Netherlands
2545 CH
+31 (0)70 359 2004
J.Kerkhoffs@hagaziekenhuis.nl

Additional identifiers

Protocol serial number
NTR909

Study information

Scientific Title

Acronym
The marker study

Study objectives
Efficacy of transfusion support depends on disease and treatment related patient factors. Markers of endothelial damage have been identified, but until today not in relation to the efficacy of transfusions.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Non-randomised, parallel group clinical trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Sickle cell disease

Interventions
Patients with a haemato-oncological diagnosis will receive platelet transfusion and patients with sickle cell disease will receive red blood cell exchange. Two blood samples will be drawn, before and after this intervention, and these samples will be used to test several known markers of endothelial cell activation/damage.

Intervention Type
Other

Phase
Not Specified

Primary outcome(s)
Efficacy of platelet transfusion or red blood cell exchange transfusion in haemato-oncological patients and sickle cell patients, respectively, in relation to several endothelial activation markers.

Key secondary outcome(s))
No secondary outcome measures

Completion date
01/04/2008

Eligibility

Key inclusion criteria
1. Age greater than 18 years
2. Haemato-oncological disease
3. Sickle cell disease
4. Informed consent

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Lower age limit
18 years

Sex
Not Specified

Key exclusion criteria
1. Active cardiovascular disease
2. Recent thrombo-embolism

Date of first enrolment
01/04/2007

Date of final enrolment
01/04/2008

Locations

Countries of recruitment
Netherlands

Study participating centre
Haga Hospital
Den Haag
Netherlands
2545 CH

Sponsor information

Organisation
Sanquin Blood Bank South West Region (The Netherlands)

ROR
https://ror.org/01fm2fv39

Funder(s)

Funder type
Hospital/treatment centre

Funder Name
Sanquin Blood Bank South West Region (The Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration